Maximus (MMS) Rating Lowered to Hold at Zacks Investment Research


Zacks Investment Research cut shares of Maximus (NYSE:MMS) from a buy rating to a hold rating in a research note published on Wednesday morning.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “


Get Maximus alerts:

A number of other brokerages have also recently issued reports on MMS. First Analysis raised Maximus from an equal rating to a weight rating and upped their target price for the company from $73.00 to $81.00 in a research report on Tuesday, May 8th. Maxim Group reissued a hold rating and issued a $69.00 target price (up from $66.00) on shares of Maximus in a research report on Thursday, February 8th. Finally, Canaccord Genuity decreased their target price on Maximus from $71.00 to $65.00 and set a hold rating for the company in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Maximus has an average rating of Hold and a consensus price target of $71.00.


Maximus opened at $62.24 on Wednesday, MarketBeat Ratings reports. The stock has a market cap of $4.06 billion, a PE ratio of 19.45, a price-to-earnings-growth ratio of 2.40 and a beta of 1.13. Maximus has a 1 year low of $58.58 and a 1 year high of $72.71.

Maximus (NYSE:MMS) last announced its earnings results on Thursday, May 10th. The health services provider reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.02). The firm had revenue of $612.79 million during the quarter, compared to analyst estimates of $617.97 million. Maximus had a net margin of 9.15% and a return on equity of 21.67%. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period last year, the company earned $0.80 earnings per share. equities research analysts predict that Maximus will post 3.24 earnings per share for the current year.


The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 31st. Shareholders of record on Tuesday, May 15th will be paid a dividend of $0.045 per share. This represents a $0.18 annualized dividend and a yield of 0.29%. The ex-dividend date is Monday, May 14th. Maximus’s dividend payout ratio is presently 5.94%.

In other Maximus news, CEO Richard A. Montoni sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $67.89, for a total transaction of $2,036,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Russell A. Beliveau sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $66.55, for a total value of $66,550.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,000 shares of company stock valued at $2,777,450. 3.10% of the stock is owned by company insiders.


Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its stake in shares of Maximus by 2.7% during the 1st quarter. BlackRock Inc. now owns 6,852,749 shares of the health services provider’s stock worth $457,354,000 after buying an additional 178,208 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Maximus by 3.1% during the 1st quarter. Victory Capital Management Inc. now owns 3,388,961 shares of the health services provider’s stock worth $226,180,000 after buying an additional 100,646 shares in the last quarter. Van Berkom & Associates Inc. raised its stake in shares of Maximus by 3.9% during the 1st quarter. Van Berkom & Associates Inc. now owns 1,200,823 shares of the health services provider’s stock worth $80,143,000 after buying an additional 45,574 shares in the last quarter. Brown Advisory Inc. raised its stake in shares of Maximus by 0.8% during the 4th quarter. Brown Advisory Inc. now owns 1,187,070 shares of the health services provider’s stock worth $84,973,000 after buying an additional 9,106 shares in the last quarter. Finally, Mondrian Investment Partners LTD raised its stake in shares of Maximus by 27.3% during the 1st quarter. Mondrian Investment Partners LTD now owns 923,505 shares of the health services provider’s stock worth $62,457,000 after buying an additional 197,808 shares in the last quarter. 97.11% of the stock is owned by hedge funds and other institutional investors.


About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.

Get a free copy of the Zacks research report on Maximus (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *